Kossel Medtech's 'Sugacoated®' Constrained Peripheral Balloon Catheter Receives NMPA Class III Approval

Recently, Sugacoated® Peripheral Vascular Constrained Balloon Dilation Catheter ("Sugar-coated haws" Balloon), independently developed by Kossel Medtech (Suzhou) Co., Ltd., a company within Medpark, has been approved for marketing by the National Medical Products Administration (NMPA).

"糖葫芦" Balloon for Peripheral Vascular Stenosis Expansion, with Unique Nitinol Wire Constraint, Provides Controllable and Uniform Expansion, Achieves Plaque Remodeling, Reduces Dissection Occurrence and Rescue Stent Implantation, Lowering Medical Costs.

Constrained Expansion Reduces Dissection

Nickel-titanium restraint wire divides the balloon longitudinally and transversely, forming convex compartments and decompression grooves.

01 Balloon convex equilibrium releases pressure, expansion is orderly and controllable;

02 Pressure-relief groove buffers stress and reduces restrictive interlayer;

03 Nickel-Titanium Constrained Wire Reduces Shear Force and Lowers Vascular Injury.

The approval and market launch of the "Sugar Gourd" balloon means that there is now a breakthrough balloon in terms of technology and concept on the market. It also adds another powerful tool for the treatment of lower limb vascular diseases, providing doctors and patients with a vascular dilation device that has greater clinical advantages.

Kossel Medtech (Suzhou) Co., Ltd

Kossel Medtech was founded in November 2013 and is located in the Jiangsu Medical Device Technology Park. It is a platform enterprise with comprehensive R&D and production capabilities for vascular interventional medical devices, dedicated to providing systematic solutions for clinical use.

Kossel Medtech has established multiple business sectors. The parent company focuses on building a one-stop treatment system in the peripheral intervention field, with its first innovative product, the umbrella-shaped long-term caval filter Octoparms@, already approved for marketing. Its subsidiary Haiyu Xincheng is dedicated to the electrophysiology field, providing comprehensive solutions for treating tachyarrhythmia. Subsidiary Mixin Medtech concentrates on the development of products in the coronary intervention field and the localization of overseas products and technologies. Subsidiary Haiwang Medtech is committed to the research and development of core raw materials that address critical bottlenecks.

Jiangsu Medical Device Science and Technology Industrial Park (Medpark) is a national-level medical device science and technology industrial park jointly built by Suzhou New District and the Suzhou Institute of Biomedical Engineering Technology of the Chinese Academy of Sciences. The operating entity is Suzhou Medical Device Industry Development Group Co., Ltd., which is responsible for coordinating the resources of Suzhou New District, relying on three core capabilities: "carrier development and construction + park operation + industrial investment," focusing on the development of the medical device industry. Medpark comprehensively sorts out the development situation of the industry, targeting five major fields: in vitro diagnostics, high-end implantable devices, high-end medical imaging, and digital healthcare, leveraging the leading role of leading enterprises and research institute platforms to accelerate the cultivation of high-quality projects. Over the past decade, Medpark has focused on developing the medical device industry, striving to create a high-end medical device industry highland with uniqueness, leadership, and标志性. It has successively received national honorary titles such as the National Torch Program Medical Device Special Industry Base, the National Innovative Medical Device Industry Cluster Pilot, the National Medical Device Professional Incubator, and the National Demonstration Unit for the Construction of a Technological Entrepreneurship Incubation Chain.